Exelixis Notches Win Against MSN Laboratories

January 19, 2023

WILMINGTON, DE – After a week-long bench trial held in Delaware in May, Judge Richard Andrews ruled in Exelixis’ favor this past Thursday, rejecting MSN’s challenge to the cabozantinib compound patent (U.S. 7,579,473).

Impact Trial’s team members working with the WilmerHale team were Thomas S.Y. LeeAddison MoyerAlan BuiAlison Von Dollen, CMIRebecca LavernoichBrian LeeJeff WoodburyJohn ChristopherMary KogerMegan BishopMelissa PomerantzNova HayesOuliana Nikolaeva-Hir, and Stu Lucero.

Congratulations to the WilmerHale team, our Impact Trial members, and Exelixis!

The case is Exelixis, Inc. (Exelixis) v. MSN Laboratories Private Limited et al. (MSN), Action No. 19-2017 (Consolidated), in the U.S. District Court for the District of Delaware.